Valneva SE Sponsored ADR (NASDAQ:VALN) Given Consensus Recommendation of “Hold” by Brokerages

Valneva SE Sponsored ADR (NASDAQ:VALN) has earned a consensus rating of “Hold” from the five brokerages that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $11.9750.

VALN has been the topic of a number of recent analyst reports. Wall Street Zen upgraded Valneva from a “strong sell” rating to a “sell” rating in a research report on Monday, June 1st. Guggenheim set a $11.00 price target on shares of Valneva in a research note on Thursday, April 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valneva in a report on Thursday, June 18th. Finally, The Goldman Sachs Group cut shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price objective for the company. in a research report on Wednesday, April 22nd.

Valneva Stock Down 1.0%

NASDAQ VALN opened at $5.18 on Friday. The business has a fifty day moving average price of $5.24 and a two-hundred day moving average price of $7.08. The company has a debt-to-equity ratio of 2.14, a current ratio of 2.14 and a quick ratio of 1.60. Valneva has a fifty-two week low of $4.75 and a fifty-two week high of $12.25. The stock has a market capitalization of $491.53 million, a PE ratio of -2.77 and a beta of 1.77.

Valneva (NASDAQ:VALN) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.42) earnings per share (EPS) for the quarter. Valneva had a negative net margin of 88.87% and a negative return on equity of 107.63%. The business had revenue of $35.77 million during the quarter. Equities analysts expect that Valneva will post -1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of VALN. XTX Topco Ltd acquired a new stake in shares of Valneva during the 4th quarter valued at $94,000. JPMorgan Chase & Co. acquired a new position in Valneva in the 3rd quarter worth about $124,000. Marex Group plc bought a new position in Valneva in the second quarter valued at about $64,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in Valneva in the fourth quarter valued at about $44,000. 11.39% of the stock is currently owned by institutional investors and hedge funds.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.